Carlos Karla, Prado Gilmar F, Teixeira Camila Dm, Conti Cristiane, de Oliveira Marcio M, Prado Lucila Bf, Carvalho Luciane Bc
Department of Neurology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
Department of Morphology, Universidade Federal do Maranhão, Av. dos Portugueses, 1966, Bacanga, São Luis, Maranhão, Brazil, 65080-805.
Cochrane Database Syst Rev. 2017 Mar 20;3(3):CD006939. doi: 10.1002/14651858.CD006939.pub2.
Restless legs syndrome (RLS) is a common disease affecting about 5% to 15% of the population. Symptoms of RLS can be severe in a minority of and can have a major impact on sleep, mostly sleep initiation, and quality of life. Benzodiazepines are drugs that can induce and maintain sleep and, hence, intuitively are thought to be beneficial to people with RLS. Altough benzodiazepines, particularly clonazepam, are used to treat RLS symptoms, a systematic review done by the American Academy of Sleep Medicine stated that benzodiazepines should not be used as a first-line treatment, although could be used as a coadjuvant therapy.
To evaluate the efficacy and safety of benzodiazepine compared to placebo or other treatment for idiopathic RLS, including unconfounded trials comparing benzodiazepines versus open control.
In March 2016 we searched CENTRAL, MEDLINE, Embase and LILACS We checked the references of each study and contacted study authors to identify any additional studies. We considered studies published in any language.
Randomised clinical trials of benzodiazepine treatment in idiopathic RLS.
We did not perform data collection and analysis, since we did not include any studies, MAIN RESULTS: We did not identify any studies that met the inclusion criteria of the review. Two cross-over studies are awaiting classification because the cross-over trials did not give data at the end of the first cross-over period.
AUTHORS' CONCLUSIONS: The effectiveness of benzodiazepines for RLS treatment is currently unknown.
不宁腿综合征(RLS)是一种常见疾病,影响着约5%至15%的人口。RLS的症状在少数患者中可能很严重,并且会对睡眠产生重大影响,主要是入睡困难以及生活质量。苯二氮䓬类药物是能够诱导和维持睡眠的药物,因此直观上被认为对RLS患者有益。尽管苯二氮䓬类药物,尤其是氯硝西泮,被用于治疗RLS症状,但美国睡眠医学学会进行的一项系统评价指出,苯二氮䓬类药物不应作为一线治疗药物,不过可作为辅助治疗药物使用。
评估苯二氮䓬类药物与安慰剂或其他治疗特发性RLS的方法相比的疗效和安全性,包括比较苯二氮䓬类药物与开放对照的无混杂因素试验。
2016年3月,我们检索了Cochrane中心对照试验注册库(CENTRAL)、医学期刊数据库(MEDLINE)、荷兰医学文摘数据库(Embase)和拉丁美洲及加勒比地区卫生科学数据库(LILACS)。我们查阅了每项研究的参考文献,并联系了研究作者以确定任何其他研究。我们考虑了以任何语言发表的研究。
苯二氮䓬类药物治疗特发性RLS的随机临床试验。
由于我们未纳入任何研究,因此未进行数据收集与分析。主要结果:我们未识别出任何符合该综述纳入标准的研究。两项交叉试验正在等待分类,因为交叉试验在第一个交叉期结束时未给出数据。
目前尚不清楚苯二氮䓬类药物对RLS治疗的有效性。